

Low Molecular Weight Prescribing Pathways in East Kent

Obstetric LMWH Prescribing Pathways

The pathways in the table below were agreed at a meeting on 23.6.22 with K&M LMC Representative, Consultant Haematologist EKHUFT, GP K&M CCG Clinical Prescribing Lead, O&G Consultant EKHUFT, Head of Quality Maternity and Neonatal Services Kent and Medway Local Maternity System (LMNS), Clinical lead for Kent and Medway LMS, Senior Programme Manager Maternity K&M ICB, Neonatal and Perinatal Mental Health, and O&G Care Groups Operations Director EKHUFT.

LMWH Obstetric Rxing Pathway	Prescribing Pathway agreed 23.6.22
Obstetrics - high risk from day 1 of pregnancy including IVF patients (LMWH during IVF treatment will be prescribed by the IVF centre)	All prescribing in East Kent to remain with EKHUFT
Obstetrics -High risk identified at 8-10 week midwife booking appointment	All prescribing in East Kent to remain with EKHUFT
Obstetrics - treatment of DVT/PE	All prescribing in East Kent to remain with EKHUFT
Obstetrics - post natal treatment	No change- full supply given by EKHUFT
Obstetrics- COVID	No change- full supply given by EKHUFT

If an un-booked patient who needs thromboprophylaxis from day 1 (pathway 1) contacts a GP, the GP may contact Advice and Guidance (Haematology) at EKHUFT.

Non-obstetric LMWH Prescribing Pathways

The following pathways were agreed by the former East Kent Prescribing Group (EKPG) in January 2020. An agreement with Oncology for patients undergoing chemotherapy was not reached, and the EKPG therefore agreed an interim solution.

INDICATION	INITIATION BY	AMOUNT TO BE SUPPLIED ON INITIATION	REPEAT SUPPLIES BY	COMMENTS
Suspected DVT treatment	GP prior to ultra sound scan on advice of DVT clinic	Until diagnosis/ therapeutic INR	Not required	
Suspected PE treatment	EKHUFT	Until diagnosis/ therapeutic INR	Not required	
Surgical procedures - prophylaxis	EKHUFT	2-6 week supply as appropriate to surgical procedure	Not required	
Surgical procedures - Bridging and peri-operative use	EKHUFT	As appropriate	Not required	
Oncology - For patients undergoing chemotherapy	Interim arrangement. East Kent Prescribing Group advise that while it is preferable that supplies are made by EKHUFT, GPs could prescribe if they have received written information confirming the drug, dose and monitoring needed.			
Oncology - Patient requiring ongoing enoxaparin treatment following	GP - on receipt of letter from haematologist confirming need for ongoing treatment and duration	On- going treatment	GP	

Approved by: IMOC
Approval date: Feb 2024
Review date: Feb 2026

completion of chemotherapy				
Contraindications to oral anticoagulants	EKHUFT	2 weeks	GP	For existing patients consider review by haematology as DOAC may now be appropriate
Lower limb immobilisation	EKHUFT; KCHFT; Other Minor Injuries providers	Full supply	n/a	
Superficial Thrombophlebitis	EKHUFT	Full supply	n/a	